Acquired Thrombotic Thrombocytopenic Purpura

DrugDrug NameDrug Description
DB06081CaplacizumabA von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP).
DrugDrug NameTargetType
DB06081Caplacizumabvon Willebrand factortarget
DrugDrug NamePhaseStatusCount
DB15094Anfibatide2Not Yet Recruiting1
DB06081Caplacizumab2Completed1
DB06081Caplacizumab3Active Not Recruiting1
DB06081Caplacizumab3Completed1